Deutsche Bank AG Acquires New Position in Upstream Bio, Inc. $UPB

Deutsche Bank AG bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 241,447 shares of the company’s stock, valued at approximately $1,671,000.

A number of other hedge funds also recently added to or reduced their stakes in UPB. Norges Bank purchased a new stake in shares of Upstream Bio during the fourth quarter worth $78,264,000. UBS Group AG grew its stake in Upstream Bio by 563.4% during the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock worth $49,039,000 after purchasing an additional 1,533,972 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Upstream Bio in the 4th quarter valued at about $41,423,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Upstream Bio by 2,049.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company’s stock valued at $9,006,000 after buying an additional 954,072 shares during the period. Finally, SEB Asset Management AB purchased a new position in shares of Upstream Bio in the 1st quarter valued at about $7,906,000.

Upstream Bio Trading Down 1.5%

Shares of NASDAQ:UPB opened at $6.69 on Friday. The firm has a 50 day simple moving average of $6.95 and a 200-day simple moving average of $8.31. Upstream Bio, Inc. has a twelve month low of $5.85 and a twelve month high of $33.68. The company has a market capitalization of $366.41 million, a PE ratio of -2.31 and a beta of 1.26.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The firm had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.56 million. As a group, equities research analysts predict that Upstream Bio, Inc. will post -2.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Weiss Ratings upgraded shares of Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. HC Wainwright started coverage on Upstream Bio in a report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 target price on the stock. Mizuho cut their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Finally, JPMorgan Chase & Co. raised their price target on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Upstream Bio currently has an average rating of “Hold” and a consensus price target of $29.67.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.